Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Jelgava – page 11

210 clinical trials in Jelgava, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Jelgava at a glance
210
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

210 trials in Jelgava

Open in trial search

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Serplulimab
  • Sponsor:Shanghai Henlius Biotech Inc.

Pneumonia+1

Not recruiting

A study testing trimodulin in hospitalized adult patients with community-acquired pneumonia including COVID-19 pneumonia

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Embolism venous

Not recruiting

Comparison of SRSD107 and enoxaparin to prevent blood clots in adults undergoing knee replacement surgery

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Sirius Therapeutics Inc.

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies

Investigational
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Jelgava

What the registry says about research in the country

01 Diabetes Management Studies

Clinical investigations focusing on type 2 diabetes management through combination therapy approaches. Research evaluates the effectiveness of gliclazide MR when combined with existing treatments.

  • Treatment Optimization
  • Glycemic Control
  • Combination Therapy

Studies aim to improve blood sugar control in patients not achieving optimal results with current medications.

02 Diabetic Eye Disease Research

Groundbreaking research examining the impact of semaglutide on diabetic retinopathy in patients with type 2 diabetes. This long-term safety study evaluates treatment effects on eye health.

  • Retinopathy Development
  • Disease Progression
  • Ophthalmologic Assessment

The research includes standardized ophthalmic evaluations to monitor disease progression and treatment outcomes.

03 Therapeutic Safety Studies

Post-authorization safety assessments conducted under European Medicines Agency oversight, focusing on long-term effects of diabetes treatments.

  • Safety Monitoring
  • Long-term Outcomes
  • Treatment Effects

These studies contribute to understanding the complete safety profile of new diabetes medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.